L’hypertrophie du ventricule gauche (HVG) est un processus adaptif et compensatoire qui se développe conséquemment à l’hypertension artérielle pour s’opposer à l’élévation chronique de la pression artérielle. L’HVG est caractérisée par une hypertrophie des cardiomyocytes suite à l’augmentation de la synthèse d’ADN, une prolifération des fibroblastes, une augmentation du dépôt de collagène et une altération de la matrice extracellulaire (MEC). Ces changements génèrent des troubles de relaxation et mènent au dysfonctionnement diastolique, ce qui diminue la performance cardiaque. La suractivité du système nerveux sympathique (SNS) joue un rôle essentiel dans le développement de l’hypertension artérielle et de l’HVG à cause de la libération excessive des catécholamines et de leurs effets sur la sécrétion des cytokines pro-inflammatoires et sur les différentes voies de signalisation hypertrophiques et prolifératives. Le traitement antihypertenseur avec de la moxonidine, un composé sympatholytique d’action centrale, permet une régression de l’HVG suite à une réduction soutenue de la synthèse d'ADN et d’une stimulation transitoire de la fragmentation de l'ADN qui se produit au début du traitement. En raison de l’interaction entre l’HVG, les cytokines inflammatoires, le SNS et leurs effets sur les protéines de signalisation hypertrophiques, l’objectif de cette étude est de détecter dans un modèle animal d’hypertension artérielle et d’HVG, les différentes voies de signalisation associées à la régression de l’HVG et à la performance cardiaque. Des rats spontanément hypertendus (SHR, 12 semaines) ont reçu de la moxonidine à 0, 100 et 400 µg/kg/h, pour une période de 1 et 4 semaines, via des mini-pompes osmotiques implantées d’une façon sous-cutanée. Après 4 semaines de traitement, la performance cardiaque a été mesurée par écho-doppler. Les rats ont ensuite été euthanasiés, le sang a été recueilli pour mesurer les concentrations des cytokines plasmatiques et les cœurs ont été prélevés pour la détermination histologique du dépôt de collagène et de l'expression des protéines de signalisation dans le ventricule gauche. Le traitement de 4 semaines n’a eu aucun effet sur les paramètres systoliques mais a permis d’améliorer les paramètres diastoliques ainsi que la performance cardiaque globale. Par rapport au véhicule, la moxonidine (400 µg/kg/h) a permis d’augmenter transitoirement la concentration plasmatique de l’IL-1β après une semaine et de réduire la masse ventriculaire gauche. De même, on a observé une diminution du dépôt de collagène et des concentrations plasmatiques des cytokines IL-6 et TNF-α, ainsi qu’une diminution de la phosphorylation de p38 et d’Akt dans le ventricule gauche après 1 et 4 semaines de traitement, et cela avec une réduction de la pression artérielle et de la fréquence cardiaque. Fait intéressant, les effets anti-hypertrophiques, anti-fibrotiques et anti-inflammatoires de la moxonidine ont pu être observés avec la dose sous-hypotensive (100 µg/kg/h). Ces résultats suggèrent des effets cardiovasculaires bénéfiques de la moxonidine associés à une amélioration de la performance cardiaque, une régulation de l'inflammation en diminuant les niveaux plasmatiques des cytokines pro-inflammatoires ainsi qu’en inhibant la MAPK p38 et Akt, et nous permettent de suggérer que, outre l'inhibition du SNS, moxonidine peut agir sur des sites périphériques. / Left ventricular hypertrophy (LVH) is an adaptive and compensatory process that develops in hypertension to oppose the chronic elevation of blood pressure. LVH is characterized by hypertrophy of cardiomyocytes following the increase in DNA synthesis, proliferation of fibroblasts, increased collagen deposition and alteration of the extracellular matrix (ECM). These changes generate relaxation and diastolic dysfunction which reduced cardiac performance. The overactivity of the sympathetic nervous system plays an essential role in the development of hypertension and left ventricular hypertrophy pathogenesis due to the excessive release of catecholamines and norepinephrine spillover and their effects on the secretion of pro-inflammatory cytokines and hypertrophic signaling pathways. Antihypertensive treatment with moxonidine, a centrally acting sympatholytic imidazoline compound, results in prevention of left ventricular hypertrophy, resulting from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation that occur early after treatment. Due to the interaction between LVH, inflammatory cytokines, the SNS and their effects on hypertrophic signaling proteins, the objective of this study is to detect in an animal model of hypertension and LVH, the different signaling pathways associated with regression of LVH and cardiac performance. Spontaneously hypertensive rats (SHR, 12 weeks old) received moxonidine at 0, 100 and 400 µg/kg/h, for 1 and 4 weeks, via subcutaneously implanted osmotic minipumps. After 4 weeks of treatment, cardiac performance was measured by echo-Doppler. Then the rats were euthanized, blood was collected for measurement of plasma cytokines and hearts for histologic determination of collagen deposition and for measurement of left ventricular expression of downstream signaling proteins. Treatment for 4 weeks had no effect on systolic parameters but improved diastolic parameters and global cardiac performance. Compared to vehicle, moxonidine (400 µg/kg/h) transiently increased plasma IL-1β after 1 week and reduced left ventricular mass. Similarly, there was a decrease in collagen deposition and plasma concentrations of IL-6 and TNF-α, and decreased phosphorylation of p38 and Akt in the left ventricle after 1 and 4 weeks treatment, in association with reduced blood pressure and heart rate. Interestingly, the anti-hypertrophic, anti-fibrotic, and anti-inflammatory effects of moxonidine were observed with a sub-hypotensive dose (100µg/kg/h). These results suggest the beneficial cardiovascular effects of moxonidine associated with improved cardiac performance, regulation of inflammation by decreasing pro-inflammatory plasma levels, inhibition of p38 MAPK and Akt, and allow us to suggest that besides inhibiting the SNS, moxonidine may act on peripheral sites.

Herzinsuffizienz mit konsekutivem Herzversagen ist ein zentrales kardiovaskuläres Problem der heutigen Bevölkerung.Ursächlich ist insbesondere eine progrediente Herzhypertrophie. Die Calcium-Calmodulin abhängige Phosphatase Calcineurin (CnR) spielt hierbei in der Pathogenese eine entscheidende Rolle. CnR wird über seine Calciumbindungsstellen an der regulatorischen Untereinheit Calcineurin B (CnB) aktiviert.Um zu untersuchen, inwieweit CnB bei der Hypertrophie verschiedener Ätiologien reguliert wird, wurde in linksventrikulären Myokardbiopsien von Patienten mit Aortenstenose (AS= 14) bzw. aus explantierten Herzen mit Dilatativer Kardiomyopathie (DCM=27) und Koronarer Herzerkrankung (KHK=7) der mRNA-und Proteingehalt von CnB bestimmt und mit der Expression von ANP und BNP korreliert. Als Kontrollgruppe dienten 15 abgelehnte Spenderherzen mit normaler systolischer Funktion und gesunder Morphologie. In den Herzen der Kontroll-, DCM-, und KHK-Gruppen wurde der linksventrikuläre Fibrosegehalt bestimmt. Hierzu wurden eine extern standardisierte Real-Time-PCR-Technik und ein etabliertes Western Blot Verfahren angewandt. Die Ergebnisse werden im Median ± 25%/75%-Perzentile angegeben und mit dem Mann-Whitney-Test bzw. Korrelationsanalysen nach Spearman berechnet. In den Herzen mit DCM zeigte sich eine signifikante Erhöhung der CnB mRNA auf ca. das Dreifache der Kontrollen (293% der Ko, p / Heart failure is a central cardiovascular problem for the current population. Cardiac hypertrophy is a central factor. The calcium-Calmodulin dependent phosphatase Calcineurin (CnR) plays a crucial role in the pathogenesis. CnR is activated via its calcium-binding site in the regulatory subunit Calcineurin B (CnB). In order to examine, to what extent CnB is regulated in different aetiologies of hypertrophy, we analysed CnB´s mRNA and protein in left ventricular samples from patients with aortic valve stenosis (AS = 14) and from explanted hearts with dilated (DCM=27) and ischemic (ICM=7) cardiomyopathy and correlated them with the expression of ANP and BNP. As a control, 15 rejected donor hearts with normal systolic function and non-pathologic changed morphology were used. Fibrosis of the left ventricle was determined in three groups: control , DCM and ICM. Therefore, we used an externally standardized real-time PCR and an established Western Blot. Data are given as median ± 25%/75%- percentiles; Mann Whitney test and Spearman´s correlation-analyses were used. CnB mRNA was significantly raised in DCM (293% of control, p

Tem sido demonstrado que a redução da sensibilidade do barorreflexo é um marcador independente de risco de mortalidade. O barorreflexo arterial tem um papel importante na manutenção e na estabilidade da pressão arterial (PA) momento a momento. Embora a variabilidade da pressão arterial (VPA) seja conhecida como contribuinte para a morbidade e mortalidade, os mecanismos pelos quais a VPA causa lesões de órgãos alvo ainda não estão bem entendidos. No presente estudo, testamos a hipótese de que o prejuízo do barorreflexo, com ou sem o aumento da PA, pode induzir o remodelamento cardíaco e da artéria pulmonar por alterar a modulação autonômica comandada pelos barorreceptores arteriais sobre coração e vasos. Para tanto, foi investigado em ratos normotensos e hipertensos o efeito da disfunção barorreflexa (10 semanas após desnervação sinoaórtica- DSA) nas alterações hemodinâmicas, no remodelamento cardíaco e no remodelamento da artéria pulmonar. A função e a morfologia cardíaca de ratos machos Wistar e SHR (GN e GH) foram avaliadas pelo ecocardiograma e por histologia. A pressão arterial foi gravada diretamente. A hipertrofia ventricular foi expressa pela relação entre peso doventrículo esquerdo (VE) e peso do ventrículo direito (VD) pelo peso corporal do rato (PC). A VPA foi avaliada pelo domínio do tempo e da freqüência. A expressão gênica pela quantificação do mRNA do peptídio natriurérito (ANP), da alfa-actina esquelética (-actina), do colágeno tipo I e tipo III foi avaliada pelo RT-PCR. A PA estava maior no grupo SHR quando comparada ao normotenso, mas a DSA não alterou os valores de PA nos grupos normotenso e hipertenso. A VPA sistólica mostrou-se maior nos grupos com DSA. Como esperado, a resposta barorreflexa estava reduzida nos grupos com DSA. Os componentes LF e HF da VFC estavam maiores nos grupos GH e GHD. Entretanto, o componente HF da VFC estava menor em GHD quando comparado ao GH. O tempo de aceleração da artéria pulmonar estava reduzido nos grupos com DSA. Adicionalmente, a DSA prejudicou a função diastólica no VE: (GN: 5,80,19 vs GD: 8,00,29 e GH: 8,20,54 vs GHD: 13,50,84 mmHg) e no VD (GN: 3,50,15 vs WD: 4,850,15 e HC: 5,830,31 vs HD: 7,770,25 mmHg). A DSA induziu hipertrofia ventricular direita e esquerda de acordo com o índice de VE e VD/ PC (9% no GD e 10% no GHD) e (25% no GD e 34% no GHD) respectivamente, bem como a DSA induziu aumento de colágeno no VE (de 1,6-vezes no GD e 2-vezes no GHD), no VD (2,9-vezes no GD e 1,15-vezes no GHD), e na artéria pulmonar (3,38-vezes no GD e 1,53-vezes no GHD). Além disso, a DSA aumentou a expressão de colágeno tipo I no VE (6,7-vezes no GD e 1,6-vezes no GHD) e VD (5,7-vezes no GD e 5,3-vezes no GHD); de colágeno tipo III no VE (3-vezes no GD e 2-vezes no GHD) e VD (4,6-vezes no GD e 2,4-vezes no HD). A desnervação aumentou, nos ratos normotensos, a expressão de ANP no VE (1,8-vezes) e no VD (1,8-vezes), de -actina no VE (3,7-vezes) e VD (1,2-vezes). Entretanto, apenas o grupo GHD aumentou a expressão de -actina no VD (1,9-vezes). Nossos resultados demonstraram que o prejuízo da função barorreflexa ocasionado pela DSA, sem modificações na PA, induziu importantes ajustes na estrutura cardíaca caracterizados pela hipertrofia do VE e do VD, bem como na indução da hipertensão pulmonar. Estas mudanças podem sugerir que a disfunção barorreflexa isolada pode modular lesões de tecidos alvo / It has been demonstrated that reduced baroreflex sensitivity is an independent marker of mortality risk. The arterial baroreflex plays an important role in the maintenance of the moment-to-moment stability of blood pressure (BP). Although the contribution of blood pressure variability (BPV) to cardiovascular morbidity and mortality is well established, the mechanisms by which BPV causes end-organ damage process are still unknown. In the present study, we hypothesized that baroreflex impairment, with or without increase in BP, can induce cardiac and pulmonary artery remodeling by altering the autonomic modulation controlled by the arterial baroreceptors to the heart and vessels. For these purposes, it were investigated in normotensive and hypertensive rats the effects of baroreceptors dysfunction (10 weeks after sinoaortic denervation - SAD) on hemodynamic alterations and on cardiac and pulmonary arterial remodeling. Cardiac function and morphology of male normotensive Wistar (GN) and spontaneously hyperntensive (GH) intact rats which underwent SAD (GD and GHD, respectively) were assessed by echocardiography and histology. BP was directly recorded. Ventricular hypertrophy was quantified by the ratio of left ventricular weight (LVW) and right ventricular weight (RVW) to body weight (BW). BPV was quantified in the time and frequency domains. The natriuretic peptide (ANP), alpha-skeletal actin (-skelectal), collagen type I and type III genes mRNA expressions were evaluated by RT-PCR. SHR presented higher BP than Wistar rats, but SAD did not change BP values either in normotensive or in hypertensive groups. Systolic BPV was increased in both SAD groups. As expected, baroreflex responses were reduced in both SAD groups. LF and HF components of HRV were increased in GH and GHD groups. However, HF component of HRV was increased in GHD as compared to GH. The pulmonary artery acceleration time was reduced in both SAD groups. In addition, SAD impaired diastolic function in both LV (GN: 5.80.19 vs GD: 8.00.29 and GH: 8.20.54 vs GHD: 13.50.84, mmHg) and RV (GN: 3.50.15 vs GD: 4.850.15 and GH: 5.830.31 vs GHD: 7.770.25, mmHg). SAD induced LV and RV hypertrophy according to LVW and RVW/BW indexes (LV:9% in GD and 10% in GHD and RV:25% in GD and 34% in GHD), as well as, SAD induced an augment in total collagen in LV (of 1.6-fold in GD and 2-fold in GHD), in RV (2.9-fold in GD and 1.15-fold in GHD), and in pulmonary artery (3.38-fold in GD and 1.53-fold in GHD). Also, SAD increased collagen gene expression type I in LV (6.7-fold in GD and 1.6-fold in GHD) and RV (5.7-fold in GD and 5.3-fold in GHD); collagen type III in LV (3-fold in GD and 2.1-fold in GHD) and RV (4.6-fold in GD and 2.4-fold in GHD). In normotensive rats, SAD increased ANP expression in LV (1.8-fold) and in RV (1.8-fold), and -skelectal in LV (3.7-fold) and RV (1.2-fold). However, GHD group only enhanced -skelectal expression in RV (1.9-fold). Our results showed that the impairment of baroreflex function by SAD, despite not changing BP, induced important adjustments of cardiac structure characterizing LV and RV hypertrophy, as well as induced pulmonary hypertension. These changes may indicate that isolated baroreflex dysfunction can modulate target-tissue damage

A doença cardiovascular (DCV) é a principal causa de mortalidade nos pacientes com doença renal crônica (DRC) e a hipertrofia de ventrículo esquerdo (HVE), a alteração mais freqüente. A remodelação cardíaca (RC) patológica ocorre em resposta a agressões como sobrecarga de volume ou de pressão e é influenciada por ativação neurohormonal, fatores locais, inflamação, isquemia, necrose e apoptose celular. Os miócitos são as principais células envolvidas na RC. Avaliamos o papel da hiperfosfatemia e do paratormônio (PTH) em animais urêmicos. Trinta e dois ratos Wistar machos foram submetidos à paratireoidectomia (PTX) e nefrectomia (Nx), com reposição contínua de PTH em concentração fisiológica (PTHf= 0,022 ug/100g/h) ou elevada (PTHe=0,11 ug/100g/h). Os animais sham (N=16) foram operados e recebiam infusão de veículo. Apenas o conteúdo de fósforo nas dietas era diferente, ou seja: pobre=0,2% (pP) ou rica em fósforo=1,2% (rP). Dividimos os animais em 6 grupos: Sham: Sham-pP (G1), Sham-rP (G2); PTX+Nx: PTHf-pP (G3), PTHf-rP (G4), PTHe-pP (G5), PTHe-rP (G6). Semanalmente determinamos o peso e a pressão arterial caudal. Creatinina, fósforo, cálcio PTH e hematócrito foram analisados. Após 8 semanas os animais foram sacrificados. A hipertrofia e fibrose miocárdicas foram analisadas com o sistema digital Leica. O peso do coração corrigido por 100g peso corporal foi maior nos grupos G5 e G6 e apresentou uma correlação positiva com hipertrofia e fibrose miocárdica. A hipertrofia e fibrose foram menores no G3, quando comparado aos grupos Nx. A hipertrofia miocárdica foi maior no G6, evidenciando o papel do P neste processo. A fibrose mocárdica ocorreu principalmente em subendocárdio e foi mais intensa no G6. Analisamos a expressão do fator transformador de crescimento (TGF-beta) e angiotensina II que foram mais intensas nos grupos G5 e G6. As lesões das artérias coronarianas foram avaliadas de forma semi-quantitativa e os animais G5 e G6 mostraram calcificações de camada média. A expressão da alfa-actina se correlacionou negativamente com as lesões coronarianas. Nossos resultados demonstraram a importância do fósforo e PTH na fisiopatologia da DCV, sendo necessário um melhor controle destes elementos para prevenção de mortalidade nos pacientes com DRC. / Cardiovascular disease (CVD) is the leading cause of mortality in patients with chronic kidney disease (CKD), and left ventricular hypertrophy (LVH) is the most common alteration. Pathologic cardiac remodeling (CR) occurs in response to injuries such as volume or pressure overload, and it is influenced by neurohormonal activation, local factors, inflammation, ischemia, necrosis and cellular apoptosis. Myocytes are the principal cells involved in CR. We evaluated the role of hyperphosphatemia and parathyroid hormone (PTH) in uremic animals. Thirty-two male Wistar rats were submitted to parathyroidectomy (PTX) and nephrectomy (Nx), with PTH continuous replacement in physiologic concentration (PTHf=0.022ug/100g/h) or elevated (PTHe=0.11ug/100g/h). The sham animals (N=16) were operated and received vehicle infusion. Only the phosphorus content in diets was different, that is: poor = 0.2% (pP) or rich in phosphorus = 1.2% (rP). We divided the animals into 6 groups: Sham: Sham-pP (G1), Sham-rP (G2); PTX+Nx: PTHf-pP (G3), PTHf-rP (G4), PTHe-pP (G5), PTHe-rP (G6). We determined the weight and caudal blood pressure weekly. Creatinine, phosphorus, PTH calcium and hematocrit were analyzed. After 8 weeks, the animals were sacrificed. Myocardial hypertrophy and fibrosis were analyzed using Leica digital system. The weight of the heart corrected for 100g body weight was greater in groups G5 and G6 and presented a positive correlation with myocardial hypertrophy and fibrosis. Hypertrophy and fibrosis were lower in G3, when compared to Nx groups. Myocardial hypertrophy was higher in G6, determining the role of P in this process. Myocardial fibrosis occurred mainly in subendocardium and was more intense in G6. We analyzed the expression of transforming growth factor (TGF-alfa) and angiotensin II, which were more intense in groups G5 and G6. Coronary artery lesions were evaluated semiquantitatively and G5 and G6 animals showed middle layer calcifications. Expression of alfa-actin correlated negatively with coronary lesions. Our results demonstrated the importance of phosphorus and PTH in the pathophysiology of CVD; therefore, a better control of these elements is required in order to prevent mortality in patients with CKD.

A disfunção cardíaca é um dos principais desfechos da doença renal crônica, sendo que o eixo sistema renina angiotensina (SRA) é um mediador chave nessa condição. Estudos têm demonstrado que os inibidores da dipeptidil peptidase IV (IDPPIV), uma classe de drogas utilizadas no tratamento do diabetes tipo II, são capazes de exercer efeitos renoprotetores e cardioprotetores, entretanto, os efeitos dos IDDPIV sobre o tecido cardíaco frente a uma injúria renal ainda não foram descritos. Assim, esse estudo teve como objetivo investigar se a inibição da DPPIV atenua a disfunção e o remodelamento cardíaco em ratos com DRC e se esses efeitos se associam a alterações no SRA. Para este fim, ratos Wistar (N=37) com idade entre 2-3 meses, foram submetidos à nefrectomia 5/6 para indução da DRC. Após a cirurgia, os ratos foram randomizados em 2 grupos: Nx (tratados com veículo) e Nx + IDPPIV (tratados com sitagliptina - 200 mg/Kg/dia). Ratos submetidos à cirurgia fictícia foram utilizados como controles (sham). Como esperado, após oito semanas de seguimento, o grupo Nx apresentou acentuada disfunção renal. Por outro lado, nos ratos tratados com sitagliptina, a queda do ritmo de filtração glomerular (RFG) foi significativamente atenuada, bem como a creatinina sérica, albuminúria e pressão arterial caudal em relação ao grupo Nx. Curiosamente, tanto a atividade quanto a expressão proteica e gênica da DPPIV cardíaca estavam aumentadas em ratos Nx comparado aos ratos controles. As análises histológicas mostraram que os cardiomiócitos de ratos Nx apresentaram maior volume nuclear e fibrose intersticial cardíaca em relação ao sham. Por outro lado, nos ratos tratados com sitagliptina o volume nuclear dos cardiomiócitos e fibrose estavam reduzidos em relação aos ratos Nx. A função sistólica não se mostrou distinta entre os três grupos de ratos. Todavia, o tempo de relaxamento isovolumétrico (TRIV) foi maior em Nx do que em sham, como sugestivo de disfunção diastólica associada à DRC e o tratamento com sitagliptina foi capaz de atenuar o TRIV. A concentração de angiotensina II cardíaca estava aumentada nos ratos Nx em relação aos ratos sham e o tratamento com sitagliptina foi capaz de impedir sua elevação. Em conjunto, os nossos dados sugerem que a inibição da DPPIV em ratos com DRC atenua o remodelamento e a disfunção cardíaca, e que esses efeitos estão envolvidos ao menos em parte, com a redução nos níveis de angiotensina II. Esse é o primeiro trabalho a demonstrar a interação da DPPIV com o SRA intracardíaco em modelo de DRC, e abre portas para estudos envolvendo os mecanismos que levam a essa associação nas síndromes cardiorrenais / Cardiac dysfunction is one of the main outcomes of chronic kidney disease, with the axis system renin angiotensin (RAS) being a key mediator in this condition. Studies have shown that dipeptidyl peptidase IV (IDPPIV) inhibitors, a class of drugs used in the treatment of type II diabetes, are capable of exerting renoprotective and cardioprotective effects, however, the effects of IDDPIV on cardiac tissue against renal injury were not described. Thus, this study aimed to investigate whether inhibition of DPPIV attenuates cardiac dysfunction and remodeling in rats with CKD and whether these effects are associated with changes in RAS. For this purpose, Wistar rats (N = 37) aged 2-3 months were subjected to 5/6 nephrectomy for induction of CKD. After surgery, the rats were randomized into 2 groups: Nx (treated with vehicle) and Nx + IDPPIV (treated with sitagliptin - 200 mg/kg/day). Sham operated rats were used as controls. After eight weeks of treatment, we identified that the Nx group had marked renal dysfunction. On the other hand, in rats treated with sitagliptin, the decrease in RFG was significantly attenuated, as well as serum creatinine, albuminuria and caudal blood pressure in relation to the Nx group. Interestingly, both the activity and the protein and gene expression of the cardiac DPPIV were increased in Nx rats compared to the control rats. Additionally, histological analysis showed that the cardiomyocytes of Nx rats presented greater nuclear volume and cardiac interstitial fibrosis compared to sham. Conversely, in animals treated with sitagliptin the nuclear volume of cardiomyocytes and fibrosis were reduced in relation to Nx rats. Systolic function was not different among the three groups of rats. However, the isovolumic relaxation time (IVR) was higher in Nx than in sham, as suggestive of CKD-associated diastolic dysfunction and treatment with sitagliptin was able to attenuate IVRT. Cardiac angiotensin II levels were elevated in Nx rats relative to sham rats. Treatment with sitagliptin prevented their elevation. Taken together, data suggest that inhibition of DPPIV in rats with CKD attenuates remodeling and cardiac dysfunction, and that these effects are at least partially involved with the reduction in angiotensin II levels. This study is the first to demonstrate an interaction of DPPIV with the intracardiac RAS in a CKD model, and will help further studies focusing the mechanisms that lead this association in cardiorrenal syndromes

Ischämische Herzerkrankungen stellen die weltweit häufigste Todesursache dar. Das Chemokin SDF-1 zählt zu den vielversprechendsten neuen Therapietargets. Allerdings werden die dem SDF-1 Effekt zugrunde liegenden Mechanismen kontrovers diskutiert. Um den Einfluss von SDF-1 auf die Herzregeneration aufzuklären, wurden transgene Ratten generiert, welche SDF-1 in Kardiomyozyten überexprimieren. Die basale Herzfunktion war in diesen Ratten nicht verändert, jedoch zeigte sich nach Herzinfarkt eine Verschlechterung der kardialen Funktion. Des Weiteren ließen sich eine verstärkte Fibrosebildung, ein Anstieg neutrophiler Granulozyten im Blut sowie eine erhöhte Einwanderung von Makrophagen in die Herzen transgener Ratten feststellen. Dagegen waren die Anlockung von Stammzellen und die Blutgefäßneubildung nicht verändert. Diese Daten bestätigen, dass kardiales SDF-1 eine nachteilige Wirkung ausüben kann, indem es entzündliche Prozesse im geschädigten Gewebe beeinflusst. Ferner wurde ein Microarray-basiertes Screening in kardialem Gewebe nach Herzinfarkt durchgeführt. Ziel der Studie war die Identifizierung neuer Moleküle, deren Rolle bei Herzerkrankungen bislang unbekannt ist. Das Screening brachte das Glykoprotein GPNMB hervor, welches an fibrotischen Prozessen nach Gewebeschädigung beteiligt ist. Wir untersuchten das Protein mit Hilfe des DBA/2J Mausstammes, in dem kein funktionelles GPNMB vorhanden ist. Die Untersuchung dieser Mäuse ergab keine Veränderungen der basalen Herzfunktion, nach Herzinfarkt zeigte sich jedoch eine verbesserte kardiale Funktion sowie erhöhte Hämoglobinkonzentrationen im Blut. Außerdem war die Funktion von Makrophagen verändert. Darüber hinaus fanden wir erhöhte Konzentrationen von GPNMB in Plasmaproben von Patienten nach akutem Herzinfarkt. Zusammenfassend weisen die Ergebnisse darauf hin, dass GPNMB nicht nur ein vielversprechendes Therapietarget, sondern auch einen potenziellen Biomarker für ischämische Herzerkrankungen darstellt. / Ischemic heart diseases are a major cause of death worldwide due to the postmitotic state of the heart. The chemokine SDF-1 is one of the most promising novel therapeutic targets due to its ability to attract leukocytes and stem cells. However, the role of different cardiac cell types in this process remains elusive and underlying mechanisms have been controversially discussed. To clarify the role of SDF-1 and its receptor CXCR4 in myocardial regeneration, we generated transgenic rats overexpressing SDF-1 in cardiomyocytes. The function of the heart at baseline was not altered in these rats, whereas the induction of myocardial infarction resulted in impaired cardiac function and remodeling. This finding was accompanied by increased fibrosis, neutrophil blood counts and macrophage infiltration into the heart. On the other hand, stem cell recruitment and neovascularization were not altered in SDF-1 transgenic rats. In conclusion, our findings confirm that the SDF-1/CXCR4 axis can have adverse effects by affecting the inflammatory state of the healing heart. In addition, a microarray-based screening was conducted in rat hearts after myocardial infarction with the aim to discover yet unknown molecules involved in cardiac repair. This screening yielded GPNMB, a glycoprotein known to be involved in inflammatory and fibrotic processes after tissue injury. We studied the protein further using DBA/2J mice that lack functional levels of GPNMB. While the cardiac function was normal in these mice at baseline, induction of myocardial infarction revealed a preservation of cardiac function, less dilatation as well as higher red blood cell and hemoglobin levels. Moreover, the absence of GPNMB resulted in an altered activity and distribution of macrophages. We also found increased levels of GPNMB in plasma of patients after myocardial infarction. In conclusion, our findings suggest that GPNMB might constitute a novel therapeutic target and biomarker of acute ischemic heart diseases.

L’hypertrophie du ventricule gauche (HVG) est un processus adaptif et compensatoire qui se développe conséquemment à l’hypertension artérielle pour s’opposer à l’élévation chronique de la pression artérielle. L’HVG est caractérisée par une hypertrophie des cardiomyocytes suite à l’augmentation de la synthèse d’ADN, une prolifération des fibroblastes, une augmentation du dépôt de collagène et une altération de la matrice extracellulaire (MEC). Ces changements génèrent des troubles de relaxation et mènent au dysfonctionnement diastolique, ce qui diminue la performance cardiaque. La suractivité du système nerveux sympathique (SNS) joue un rôle essentiel dans le développement de l’hypertension artérielle et de l’HVG à cause de la libération excessive des catécholamines et de leurs effets sur la sécrétion des cytokines pro-inflammatoires et sur les différentes voies de signalisation hypertrophiques et prolifératives. Le traitement antihypertenseur avec de la moxonidine, un composé sympatholytique d’action centrale, permet une régression de l’HVG suite à une réduction soutenue de la synthèse d'ADN et d’une stimulation transitoire de la fragmentation de l'ADN qui se produit au début du traitement. En raison de l’interaction entre l’HVG, les cytokines inflammatoires, le SNS et leurs effets sur les protéines de signalisation hypertrophiques, l’objectif de cette étude est de détecter dans un modèle animal d’hypertension artérielle et d’HVG, les différentes voies de signalisation associées à la régression de l’HVG et à la performance cardiaque. Des rats spontanément hypertendus (SHR, 12 semaines) ont reçu de la moxonidine à 0, 100 et 400 µg/kg/h, pour une période de 1 et 4 semaines, via des mini-pompes osmotiques implantées d’une façon sous-cutanée. Après 4 semaines de traitement, la performance cardiaque a été mesurée par écho-doppler. Les rats ont ensuite été euthanasiés, le sang a été recueilli pour mesurer les concentrations des cytokines plasmatiques et les cœurs ont été prélevés pour la détermination histologique du dépôt de collagène et de l'expression des protéines de signalisation dans le ventricule gauche. Le traitement de 4 semaines n’a eu aucun effet sur les paramètres systoliques mais a permis d’améliorer les paramètres diastoliques ainsi que la performance cardiaque globale. Par rapport au véhicule, la moxonidine (400 µg/kg/h) a permis d’augmenter transitoirement la concentration plasmatique de l’IL-1β après une semaine et de réduire la masse ventriculaire gauche. De même, on a observé une diminution du dépôt de collagène et des concentrations plasmatiques des cytokines IL-6 et TNF-α, ainsi qu’une diminution de la phosphorylation de p38 et d’Akt dans le ventricule gauche après 1 et 4 semaines de traitement, et cela avec une réduction de la pression artérielle et de la fréquence cardiaque. Fait intéressant, les effets anti-hypertrophiques, anti-fibrotiques et anti-inflammatoires de la moxonidine ont pu être observés avec la dose sous-hypotensive (100 µg/kg/h). Ces résultats suggèrent des effets cardiovasculaires bénéfiques de la moxonidine associés à une amélioration de la performance cardiaque, une régulation de l'inflammation en diminuant les niveaux plasmatiques des cytokines pro-inflammatoires ainsi qu’en inhibant la MAPK p38 et Akt, et nous permettent de suggérer que, outre l'inhibition du SNS, moxonidine peut agir sur des sites périphériques. / Left ventricular hypertrophy (LVH) is an adaptive and compensatory process that develops in hypertension to oppose the chronic elevation of blood pressure. LVH is characterized by hypertrophy of cardiomyocytes following the increase in DNA synthesis, proliferation of fibroblasts, increased collagen deposition and alteration of the extracellular matrix (ECM). These changes generate relaxation and diastolic dysfunction which reduced cardiac performance. The overactivity of the sympathetic nervous system plays an essential role in the development of hypertension and left ventricular hypertrophy pathogenesis due to the excessive release of catecholamines and norepinephrine spillover and their effects on the secretion of pro-inflammatory cytokines and hypertrophic signaling pathways. Antihypertensive treatment with moxonidine, a centrally acting sympatholytic imidazoline compound, results in prevention of left ventricular hypertrophy, resulting from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation that occur early after treatment. Due to the interaction between LVH, inflammatory cytokines, the SNS and their effects on hypertrophic signaling proteins, the objective of this study is to detect in an animal model of hypertension and LVH, the different signaling pathways associated with regression of LVH and cardiac performance. Spontaneously hypertensive rats (SHR, 12 weeks old) received moxonidine at 0, 100 and 400 µg/kg/h, for 1 and 4 weeks, via subcutaneously implanted osmotic minipumps. After 4 weeks of treatment, cardiac performance was measured by echo-Doppler. Then the rats were euthanized, blood was collected for measurement of plasma cytokines and hearts for histologic determination of collagen deposition and for measurement of left ventricular expression of downstream signaling proteins. Treatment for 4 weeks had no effect on systolic parameters but improved diastolic parameters and global cardiac performance. Compared to vehicle, moxonidine (400 µg/kg/h) transiently increased plasma IL-1β after 1 week and reduced left ventricular mass. Similarly, there was a decrease in collagen deposition and plasma concentrations of IL-6 and TNF-α, and decreased phosphorylation of p38 and Akt in the left ventricle after 1 and 4 weeks treatment, in association with reduced blood pressure and heart rate. Interestingly, the anti-hypertrophic, anti-fibrotic, and anti-inflammatory effects of moxonidine were observed with a sub-hypotensive dose (100µg/kg/h). These results suggest the beneficial cardiovascular effects of moxonidine associated with improved cardiac performance, regulation of inflammation by decreasing pro-inflammatory plasma levels, inhibition of p38 MAPK and Akt, and allow us to suggest that besides inhibiting the SNS, moxonidine may act on peripheral sites.

A disfunção cardíaca é um dos principais desfechos da doença renal crônica, sendo que o eixo sistema renina angiotensina (SRA) é um mediador chave nessa condição. Estudos têm demonstrado que os inibidores da dipeptidil peptidase IV (IDPPIV), uma classe de drogas utilizadas no tratamento do diabetes tipo II, são capazes de exercer efeitos renoprotetores e cardioprotetores, entretanto, os efeitos dos IDDPIV sobre o tecido cardíaco frente a uma injúria renal ainda não foram descritos. Assim, esse estudo teve como objetivo investigar se a inibição da DPPIV atenua a disfunção e o remodelamento cardíaco em ratos com DRC e se esses efeitos se associam a alterações no SRA. Para este fim, ratos Wistar (N=37) com idade entre 2-3 meses, foram submetidos à nefrectomia 5/6 para indução da DRC. Após a cirurgia, os ratos foram randomizados em 2 grupos: Nx (tratados com veículo) e Nx + IDPPIV (tratados com sitagliptina - 200 mg/Kg/dia). Ratos submetidos à cirurgia fictícia foram utilizados como controles (sham). Como esperado, após oito semanas de seguimento, o grupo Nx apresentou acentuada disfunção renal. Por outro lado, nos ratos tratados com sitagliptina, a queda do ritmo de filtração glomerular (RFG) foi significativamente atenuada, bem como a creatinina sérica, albuminúria e pressão arterial caudal em relação ao grupo Nx. Curiosamente, tanto a atividade quanto a expressão proteica e gênica da DPPIV cardíaca estavam aumentadas em ratos Nx comparado aos ratos controles. As análises histológicas mostraram que os cardiomiócitos de ratos Nx apresentaram maior volume nuclear e fibrose intersticial cardíaca em relação ao sham. Por outro lado, nos ratos tratados com sitagliptina o volume nuclear dos cardiomiócitos e fibrose estavam reduzidos em relação aos ratos Nx. A função sistólica não se mostrou distinta entre os três grupos de ratos. Todavia, o tempo de relaxamento isovolumétrico (TRIV) foi maior em Nx do que em sham, como sugestivo de disfunção diastólica associada à DRC e o tratamento com sitagliptina foi capaz de atenuar o TRIV. A concentração de angiotensina II cardíaca estava aumentada nos ratos Nx em relação aos ratos sham e o tratamento com sitagliptina foi capaz de impedir sua elevação. Em conjunto, os nossos dados sugerem que a inibição da DPPIV em ratos com DRC atenua o remodelamento e a disfunção cardíaca, e que esses efeitos estão envolvidos ao menos em parte, com a redução nos níveis de angiotensina II. Esse é o primeiro trabalho a demonstrar a interação da DPPIV com o SRA intracardíaco em modelo de DRC, e abre portas para estudos envolvendo os mecanismos que levam a essa associação nas síndromes cardiorrenais / Cardiac dysfunction is one of the main outcomes of chronic kidney disease, with the axis system renin angiotensin (RAS) being a key mediator in this condition. Studies have shown that dipeptidyl peptidase IV (IDPPIV) inhibitors, a class of drugs used in the treatment of type II diabetes, are capable of exerting renoprotective and cardioprotective effects, however, the effects of IDDPIV on cardiac tissue against renal injury were not described. Thus, this study aimed to investigate whether inhibition of DPPIV attenuates cardiac dysfunction and remodeling in rats with CKD and whether these effects are associated with changes in RAS. For this purpose, Wistar rats (N = 37) aged 2-3 months were subjected to 5/6 nephrectomy for induction of CKD. After surgery, the rats were randomized into 2 groups: Nx (treated with vehicle) and Nx + IDPPIV (treated with sitagliptin - 200 mg/kg/day). Sham operated rats were used as controls. After eight weeks of treatment, we identified that the Nx group had marked renal dysfunction. On the other hand, in rats treated with sitagliptin, the decrease in RFG was significantly attenuated, as well as serum creatinine, albuminuria and caudal blood pressure in relation to the Nx group. Interestingly, both the activity and the protein and gene expression of the cardiac DPPIV were increased in Nx rats compared to the control rats. Additionally, histological analysis showed that the cardiomyocytes of Nx rats presented greater nuclear volume and cardiac interstitial fibrosis compared to sham. Conversely, in animals treated with sitagliptin the nuclear volume of cardiomyocytes and fibrosis were reduced in relation to Nx rats. Systolic function was not different among the three groups of rats. However, the isovolumic relaxation time (IVR) was higher in Nx than in sham, as suggestive of CKD-associated diastolic dysfunction and treatment with sitagliptin was able to attenuate IVRT. Cardiac angiotensin II levels were elevated in Nx rats relative to sham rats. Treatment with sitagliptin prevented their elevation. Taken together, data suggest that inhibition of DPPIV in rats with CKD attenuates remodeling and cardiac dysfunction, and that these effects are at least partially involved with the reduction in angiotensin II levels. This study is the first to demonstrate an interaction of DPPIV with the intracardiac RAS in a CKD model, and will help further studies focusing the mechanisms that lead this association in cardiorrenal syndromes

Hypertension is a leading risk factors associated with cardiovascular morbidity and mortality, killing millions of people every year. And in hypertension oxidative stress is increased and may be the cause or a consequence of elevated blood pressure. In recent years the exercise has been shown to be an alternative for the prevention and treatment of hypertension to lower blood pressure, as has been demonstrated the ability to strength training improve antioxidant defense in normotensive. Thus, the objectives of this work were: (1) to evaluate the effects of a low-intensity resistance exercise session on oxidative stress indicators in cardiac muscle of hypertensive rats; (2) evaluate the effects of strength training on renal and cardiac hypertrophy-induced renovascular hypertension; (3) evaluate the effects of strength training on renal oxidative stress in rats with renovascular hypertension. We verified that the power exercise can reduce oxidative damage by increasing the activity of antioxidant enzymes in the heart. These effects are similar in the kidney when it is performed strength training chronically with moderate intensity in renovascular hypertension. It was possible to verify that strength training has beneficial effects on hypertension and renovascular is able to reduce mean arterial pressure and heart rate, and reverse hypertrophy of the contralateral kidney and heart. / A hipertensão arterial é um dos principais fatores de risco associados às morbidades e mortalidade cardiovasculares, causando a morte de milhões de pessoas por ano. Na hipertensão, o estresse oxidativo está aumentado, podendo ser este o motivo ou uma consequência da elevação da pressão arterial. Nos últimos anos o exercício físico tem se mostrado como uma alternativa para a prevenção e o tratamento da hipertensão por reduzir a pressão arterial, assim como tem sido demonstrada a capacidade de o treinamento de força melhorar a defesa antioxidante em normotensos. Desta forma, os objetivos desta dissertação foram: (1) avaliar o efeito de uma sessão de exercício de força de baixa intensidade sobre os indicadores de estresse oxidativo no músculo cardíaco de ratos hipertensos; (2) avaliar os efeitos do treinamento de força sobre a hipertrofia renal e cardíaca induzida pela hipertensão renovascular; (3) avaliar os efeitos do treinamento de força sobre o estresse oxidativo renal em ratos com hipertensão renovascular. Verificamos que o exercício de força é capaz de reduzir os danos oxidativos através do aumento da atividade das enzimas antioxidantes no coração. Estes efeitos são similares no rim quando é realizado o treinamento de força de forma crônica na hipertensão renovascular. Foi possível verificar que o treinamento de força tem efeitos benéficos na hipertensão renovascular e é capaz de reduzir a pressão arterial média e frequência cardíaca, além de reverter a hipertrofia do rim contralateral e do coração.

Tem sido demonstrado que a redução da sensibilidade do barorreflexo é um marcador independente de risco de mortalidade. O barorreflexo arterial tem um papel importante na manutenção e na estabilidade da pressão arterial (PA) momento a momento. Embora a variabilidade da pressão arterial (VPA) seja conhecida como contribuinte para a morbidade e mortalidade, os mecanismos pelos quais a VPA causa lesões de órgãos alvo ainda não estão bem entendidos. No presente estudo, testamos a hipótese de que o prejuízo do barorreflexo, com ou sem o aumento da PA, pode induzir o remodelamento cardíaco e da artéria pulmonar por alterar a modulação autonômica comandada pelos barorreceptores arteriais sobre coração e vasos. Para tanto, foi investigado em ratos normotensos e hipertensos o efeito da disfunção barorreflexa (10 semanas após desnervação sinoaórtica- DSA) nas alterações hemodinâmicas, no remodelamento cardíaco e no remodelamento da artéria pulmonar. A função e a morfologia cardíaca de ratos machos Wistar e SHR (GN e GH) foram avaliadas pelo ecocardiograma e por histologia. A pressão arterial foi gravada diretamente. A hipertrofia ventricular foi expressa pela relação entre peso doventrículo esquerdo (VE) e peso do ventrículo direito (VD) pelo peso corporal do rato (PC). A VPA foi avaliada pelo domínio do tempo e da freqüência. A expressão gênica pela quantificação do mRNA do peptídio natriurérito (ANP), da alfa-actina esquelética (-actina), do colágeno tipo I e tipo III foi avaliada pelo RT-PCR. A PA estava maior no grupo SHR quando comparada ao normotenso, mas a DSA não alterou os valores de PA nos grupos normotenso e hipertenso. A VPA sistólica mostrou-se maior nos grupos com DSA. Como esperado, a resposta barorreflexa estava reduzida nos grupos com DSA. Os componentes LF e HF da VFC estavam maiores nos grupos GH e GHD. Entretanto, o componente HF da VFC estava menor em GHD quando comparado ao GH. O tempo de aceleração da artéria pulmonar estava reduzido nos grupos com DSA. Adicionalmente, a DSA prejudicou a função diastólica no VE: (GN: 5,80,19 vs GD: 8,00,29 e GH: 8,20,54 vs GHD: 13,50,84 mmHg) e no VD (GN: 3,50,15 vs WD: 4,850,15 e HC: 5,830,31 vs HD: 7,770,25 mmHg). A DSA induziu hipertrofia ventricular direita e esquerda de acordo com o índice de VE e VD/ PC (9% no GD e 10% no GHD) e (25% no GD e 34% no GHD) respectivamente, bem como a DSA induziu aumento de colágeno no VE (de 1,6-vezes no GD e 2-vezes no GHD), no VD (2,9-vezes no GD e 1,15-vezes no GHD), e na artéria pulmonar (3,38-vezes no GD e 1,53-vezes no GHD). Além disso, a DSA aumentou a expressão de colágeno tipo I no VE (6,7-vezes no GD e 1,6-vezes no GHD) e VD (5,7-vezes no GD e 5,3-vezes no GHD); de colágeno tipo III no VE (3-vezes no GD e 2-vezes no GHD) e VD (4,6-vezes no GD e 2,4-vezes no HD). A desnervação aumentou, nos ratos normotensos, a expressão de ANP no VE (1,8-vezes) e no VD (1,8-vezes), de -actina no VE (3,7-vezes) e VD (1,2-vezes). Entretanto, apenas o grupo GHD aumentou a expressão de -actina no VD (1,9-vezes). Nossos resultados demonstraram que o prejuízo da função barorreflexa ocasionado pela DSA, sem modificações na PA, induziu importantes ajustes na estrutura cardíaca caracterizados pela hipertrofia do VE e do VD, bem como na indução da hipertensão pulmonar. Estas mudanças podem sugerir que a disfunção barorreflexa isolada pode modular lesões de tecidos alvo / It has been demonstrated that reduced baroreflex sensitivity is an independent marker of mortality risk. The arterial baroreflex plays an important role in the maintenance of the moment-to-moment stability of blood pressure (BP). Although the contribution of blood pressure variability (BPV) to cardiovascular morbidity and mortality is well established, the mechanisms by which BPV causes end-organ damage process are still unknown. In the present study, we hypothesized that baroreflex impairment, with or without increase in BP, can induce cardiac and pulmonary artery remodeling by altering the autonomic modulation controlled by the arterial baroreceptors to the heart and vessels. For these purposes, it were investigated in normotensive and hypertensive rats the effects of baroreceptors dysfunction (10 weeks after sinoaortic denervation - SAD) on hemodynamic alterations and on cardiac and pulmonary arterial remodeling. Cardiac function and morphology of male normotensive Wistar (GN) and spontaneously hyperntensive (GH) intact rats which underwent SAD (GD and GHD, respectively) were assessed by echocardiography and histology. BP was directly recorded. Ventricular hypertrophy was quantified by the ratio of left ventricular weight (LVW) and right ventricular weight (RVW) to body weight (BW). BPV was quantified in the time and frequency domains. The natriuretic peptide (ANP), alpha-skeletal actin (-skelectal), collagen type I and type III genes mRNA expressions were evaluated by RT-PCR. SHR presented higher BP than Wistar rats, but SAD did not change BP values either in normotensive or in hypertensive groups. Systolic BPV was increased in both SAD groups. As expected, baroreflex responses were reduced in both SAD groups. LF and HF components of HRV were increased in GH and GHD groups. However, HF component of HRV was increased in GHD as compared to GH. The pulmonary artery acceleration time was reduced in both SAD groups. In addition, SAD impaired diastolic function in both LV (GN: 5.80.19 vs GD: 8.00.29 and GH: 8.20.54 vs GHD: 13.50.84, mmHg) and RV (GN: 3.50.15 vs GD: 4.850.15 and GH: 5.830.31 vs GHD: 7.770.25, mmHg). SAD induced LV and RV hypertrophy according to LVW and RVW/BW indexes (LV:9% in GD and 10% in GHD and RV:25% in GD and 34% in GHD), as well as, SAD induced an augment in total collagen in LV (of 1.6-fold in GD and 2-fold in GHD), in RV (2.9-fold in GD and 1.15-fold in GHD), and in pulmonary artery (3.38-fold in GD and 1.53-fold in GHD). Also, SAD increased collagen gene expression type I in LV (6.7-fold in GD and 1.6-fold in GHD) and RV (5.7-fold in GD and 5.3-fold in GHD); collagen type III in LV (3-fold in GD and 2.1-fold in GHD) and RV (4.6-fold in GD and 2.4-fold in GHD). In normotensive rats, SAD increased ANP expression in LV (1.8-fold) and in RV (1.8-fold), and -skelectal in LV (3.7-fold) and RV (1.2-fold). However, GHD group only enhanced -skelectal expression in RV (1.9-fold). Our results showed that the impairment of baroreflex function by SAD, despite not changing BP, induced important adjustments of cardiac structure characterizing LV and RV hypertrophy, as well as induced pulmonary hypertension. These changes may indicate that isolated baroreflex dysfunction can modulate target-tissue damage